Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05121545 · ClinicalTrials.gov registry record · NA

Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors

A NA study of Melanoma and Sarcoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Active
Registry status
NA
Development phase
11
Enrollment target
1
Study location

NCT05121545: Active NA study of Melanoma and Sarcoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

NCT05121545 is a NA study of Melanoma and Sarcoma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 11 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05121545, a NA study of Melanoma and Sarcoma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

This is a single arm, phase I study, evaluating the feasibility, toxicity, and degree of tumor response after novel proton pencil beam scanning (PBS GRID) treatment in patients with bulky tumors that are difficult to manage.

Primary Outcome

To assess the feasibility of successfully creating treatment plans and delivering a novel proton therapy called Pro-GRID. Feasibility will be determined by a successful intervention delivery for 10 of 12 patients with bulky solid tumors.

Conditions Studied

Interventions

  • RADIATION Pro-GRID

Study Locations (1)

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2022-04-06
Est. Completion 2026-12
Phase NA

What the registry record for NCT05121545 still lists

NCT05121545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Pro-GRID is the first listed.

NCT05121545 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT05121545 about?

NCT05121545 is a clinical study titled "Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors". This is a single arm, phase I study, evaluating the feasibility, toxicity, and degree of tumor response after novel proton pencil beam scanning (PBS GRID) treatment in patients with bulky tumors that are difficult to manage.

What is the current status of trial NCT05121545?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 11 participants. The study started on 2022-04-06. Estimated completion is 2026-12.

What conditions does trial NCT05121545 study?

This clinical trial studies the following conditions: Melanoma, Sarcoma.

What interventions are being tested in trial NCT05121545?

The interventions under investigation include: Pro-GRID (RADIATION).

Who is sponsoring clinical trial NCT05121545?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05121545 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05121545's enrollment target sits among peer trials

11 250th of 266 higher than 15 of 266 other Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05121545, the US trial registry maintained by the National Library of Medicine. NCT05121545 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.